These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 10871245)
21. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Prosser LA; Kuntz KM; Bar-Or A; Weinstein MC Value Health; 2004; 7(5):554-68. PubMed ID: 15367251 [TBL] [Abstract][Full Text] [Related]
22. The treatment of multiple sclerosis: current and future. Polman CH; Hartung HP Curr Opin Neurol; 1995 Jun; 8(3):200-9. PubMed ID: 7551119 [TBL] [Abstract][Full Text] [Related]
23. Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. Johnson KP; Due DL Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):205-14. PubMed ID: 19527092 [TBL] [Abstract][Full Text] [Related]
24. Newer versus older treatments for relapsing-remitting multiple sclerosis. Weinstock-Guttman B; Cohen JA Drug Saf; 1996 Feb; 14(2):121-30. PubMed ID: 8852526 [TBL] [Abstract][Full Text] [Related]
25. Differential mechanisms of action of interferon-beta and glatiramer aetate in MS. Yong VW Neurology; 2002 Sep; 59(6):802-8. PubMed ID: 12349849 [TBL] [Abstract][Full Text] [Related]
26. Current disease-modifying therapies in multiple sclerosis. Kieseier BC; Hartung HP Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379 [TBL] [Abstract][Full Text] [Related]
27. Neurodegeneration and clinical relevance for early treatment in multiple sclerosis. Rieckmann P Int MS J; 2005 Aug; 12(2):42-51. PubMed ID: 16417814 [TBL] [Abstract][Full Text] [Related]
28. [Current concepts on the use of some immunomodulatory drugs in the treatment of multiple sclerosis]. Correale J; Cristiano E Medicina (B Aires); 2001; 61(4):470-80. PubMed ID: 11563177 [TBL] [Abstract][Full Text] [Related]
29. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. Boggild M; Palace J; Barton P; Ben-Shlomo Y; Bregenzer T; Dobson C; Gray R BMJ; 2009 Dec; 339():b4677. PubMed ID: 19955128 [TBL] [Abstract][Full Text] [Related]
30. [Rationale for an early treatment of multiple sclerosis]. Comi G; Martino G Rev Neurol; 2000 Jun 16-30; 30(12):1265-8. PubMed ID: 10935262 [TBL] [Abstract][Full Text] [Related]
31. New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate. Cadavid D; Cheriyan J; Skurnick J; Lincoln JA; Wolansky LJ; Cook SD J Neurol Neurosurg Psychiatry; 2009 Dec; 80(12):1337-43. PubMed ID: 19687024 [TBL] [Abstract][Full Text] [Related]
32. Treatment of multiple sclerosis and related disorders: what's new in the past 2 years? Noseworthy JH Clin Neuropharmacol; 2003; 26(1):28-37. PubMed ID: 12567162 [No Abstract] [Full Text] [Related]
33. Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics. Rudick RA Arch Neurol; 1999 Sep; 56(9):1079-84. PubMed ID: 10488808 [TBL] [Abstract][Full Text] [Related]
34. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region]. Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035 [TBL] [Abstract][Full Text] [Related]
35. Disease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomes. Katrych O; Simone TM; Azad S; Mousa SA CNS Neurol Disord Drug Targets; 2009 Dec; 8(6):512-9. PubMed ID: 19811446 [TBL] [Abstract][Full Text] [Related]